Antibody-Dependent Enzyme Prodrug Therapy (ADEPT)
Authors:
- 1 January 2010
- book chapter
- Published by Springer Nature
- Vol. 9 (3) , 431-451
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Gastrointestinal stromal tumourThe Lancet, 2007
- The Epigenomics of CancerCell, 2007
- A Phase I Study of Single Administration of Antibody-Directed Enzyme Prodrug Therapy with the Recombinant Anti–Carcinoembryonic Antigen Antibody-Enzyme Fusion Protein MFECP1 and a Bis-Iodo Phenol Mustard ProdrugClinical Cancer Research, 2006
- EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumoursEuropean Journal of Cancer, 2006
- A β-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapyMolecular Cancer Therapeutics, 2005
- Glycoforms obtained by expression in Pichia pastoris improve cancer targeting potential of a recombinant antibody-enzyme fusion proteinGlycobiology, 2003
- Chimeric TNT-3/Human β -Glucuronidase Fusion Proteins for Antibody-Directed Enzyme Prodrug Therapy (ADEPT)Cancer Biotherapy and Radiopharmaceuticals, 2003
- The Hallmarks of CancerCell, 2000
- First clinical experience with ADEPTAdvanced Drug Delivery Reviews, 1996
- Phage libraries for generation of clinically useful antibodiesThe Lancet, 1994